EPRX: Eupraxia Pharma Company Aggregate Debts

Symbol and logo of brand eupraxiapharma.com (EPRX)

This daily price chart for Eupraxia Pharmaceuticals (EPRX) debt illustrates the company's financial position, where the indicator stands at 0.00. The business currently relies on external funding and hopes for successful medical trials, as the development stage of slow-release delivery systems is not yet profitable. To maintain the mobility of its scientific staff, the company has outsourced production and testing to third-party contractors, allowing it to focus on developing pain management solutions.

EPRX: Eupraxia Pharmaceuticals, Inc. Company Debts 04/06/2024 - 10/31/2026

Eupraxia Pharmaceuticals (EPRX) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Price Performance Chart eupraxiapharma.com|EPRX - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Eupraxia Pharma|EPRX - Total Company Value
- balance sheet equity data:
Accounting Value of a Share Eupraxia Pharmaceuticals|EPRX - Company Book Value|Market Cap to Net Assets Ratio eupraxiapharma.com|EPRX - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Eupraxia Pharmaceuticals|EPRX - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital eupraxiapharma.com|EPRX - Company Debts|Debts to Book Value Eupraxia Pharma|EPRX - Company Long-Term Liabilities|Amount of Current Liabilities Eupraxia Pharmaceuticals|Intermediate Coverage Ratio eupraxiapharma.com
- earnings and valuation multiples information:
EPRX - Net Profit
Fundamental company analysis:EPRX - Eupraxia Pharmaceuticals, Inc.
Signature product of Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals (EPRX) is scaling its DiffuSphere technology to develop long-acting drugs for osteoarthritis. The company's debt load dynamics reflect total borrowed funds adjusted for the current market value of the firm. Daily calculations capture the volume of raised capital during expansion periods. An increase in this metric indicates an aggressive capture of market niches; however, excessive liabilities reduce the issuer's financial resilience to external shocks.

Who Eupraxia Pharmaceuticals competes with

HLN (Haleon Corp) - Aggregate Debt Obligations|Company Aggregate Debts KVUE (Kenvue Inc.)|Company Aggregate Debts veronapharma.com VRNA|MENS - Company Debts|Aggregate Debt Obligations LGND (Ligand Pharmaceuticals Incorporated)|Amneal Pharmaceuticals Inc (AMRX) - Company Debts|Company Total Debt Perrigo Corp|ALVO (Alvotech) - Company Aggregate Debts|Company Aggregate Debts liquidia.com|Company Total Debt GLPG (Galapagos)|ANIP (ANI Pharmaceuticals Inc) - Aggregate Debt Obligations|Company Debts MannKind Corp. MNKD|Amphastar Corp (AMPH) - Company Cumulative Debt|PCRX: Company Total Debt|ars-pharma.com - Company Cumulative Indebtedness|TBPH: Company Aggregate Debts|Aquestive Therapeutics Inc - Aggregate Debt Obligations|SCPH (scPharmaceuticals, Inc.) - Company Aggregate Debts|Company Cumulative Debt Tectonic TECX|Company Debts Tonix Pharmaceuticals (TNXP)|SXTC (sxtchina.com) - Aggregate Debt Obligations|Company Aggregate Debts BHST (BioHarvest Sciences Inc.)|Invizyne Technologies (EXOZ) - Company Cumulative Debt|ORMP: Company Total Debt|ENTX - Company Aggregate Debts|MindWalk Holdings (HYFT) - Company Debts|Company Aggregate Indebtedness ABVC (abvcpharma.com)|Company Debts Cumberland Pharmaceuticals Inc.|QNTM: Aggregate Debt Obligations|Company Aggregate Debts FGEN|Company Aggregate Debts Telomir Pharmaceuticals Corp (TELO)|Rani Therapeutics Holdings, Inc. - Company Total Debt|SNYR: Company Aggregate Debt|Rallybio Corp. - Company Aggregate Debts|Company Total Debt Obligations Lexaria Bioscience LEXX|PULM: Company Aggregate Debts|Pheton Holdings (PTHL) - Company Aggregate Debts|Company Total Debt APM|LYRA: Aggregate Debt Obligations|Company Debts Impact BioMedical (IBO)|TNFA: Company Aggregate Indebtedness|Company Aggregate Debts YCBD (cbdMD)|Aggregate Debt Obligations PRFX|Auris Medical - Company Aggregate Debts|LIPO - Company Aggregate Debts|OptiNose (OPTN) - Company Debts|Pieris Pharmaceuticals Inc - Aggregate Debt Obligations|Company Debts Procaps Group SA|Company Total Debt Petros Pharma (PTPI)|Company Aggregate Debts QLI|Company Aggregate Debts acelyrin.com (SLRN)|Company Aggregate Debts TFFP (TFF Pharmaceuticals, Inc.)